Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma - European Medical Journal

Continue

Phase 2 trial of lenvatinib and everolimus for metastatic renal cell carcinoma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a randomised, phase 2, three-arm trial of lenvatinib, everolimus, and lenvatinib combined with everolimus in patients with metastatic renal cell carcinoma.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given